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Human T-lymphotropic virus 1 (HTLV-1) is a retrovirus that produces a persistent
infection. Two transmission routes (from mother to child and via sexual intercourse)
favor familial clustering of HTLV-1. It is yet unknown why most HTLV-1 carriers remain
asymptomatic while about 10% of them develop complications. HTLV-1 associated
diseases were originally described as sporadic entities, but familial presentations have
been reported. To explore what is known about family aggregation of HTLV-1-associated
diseases we undertook a systematic review. We aimed at answering whether, when,
and where family aggregation of HTLV-1-associated diseases was reported, which
relatives were affected and which hypotheses were proposed to explain aggregation.
We searched MEDLINE, abstract books of HTLV conferences and reference lists of
selected papers. Search terms used referred to HTLV-1 infection, and HTLV-1-associated
diseases, and family studies. HTLV-1-associated diseases considered are adult T-cell
leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), HTLV-1-associated uveitis, and infective dermatitis. Seventy-four records
reported HTLV-1-associated diseases in more than one member of the same family
and were included. Most reports came from HTLV-1-endemic countries, mainly Japan
(n = 30) and Brazil (n = 10). These reports described a total of 270 families in which
more than one relative had HTLV-1-associated diseases. In most families, different family
members suffered from the same disease (n = 223). The diseases most frequently
reported were ATLL (115 families) and HAM/TSP (102 families). Most families (n = 144)
included two to four affected individuals. The proportion of ATLL patients with family
history of ATLL ranged from 2 to 26%. The proportion of HAM/TSP patients with family
history of HAM/TSP ranged from 1 to 48%. The predominant cluster types for ATLL
were clusters of siblings and parent-child pairs and for HAM/TSP, an affected parent
with one or more affected children. The evidence in the literature, although weak, does
suggest that HTLV-1-associated diseases sometimes cluster in families. Whether familial
transmission of HTLV-1 is the only determining factor, or whether other factors are also
involved, needs further research.
Keywords: human T-lymphotropic virus 1, tropical spastic paraparesis, adult T-cell leukemia-lymphoma, uveitis,
family research, systematic review
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INTRODUCTION
Human T-lymphotropic virus 1 (HTLV-1) is a retrovirus that
causes a lifelong infection. HTLV-1 infects an estimated five
to ten million people worldwide (Gessain and Cassar, 2012),
heterogeneously distributed over all continents. Hyperendemic
foci (population prevalence of more than 5%) have been
identified in Japan, Australo-Melanesia, the Caribbean, South
America, and Central and West Africa. Up to 10% of the people
infected with HTLV-1 develop associated diseases (Verdonck
et al., 2007b), including (1) inflammatory diseases such
as HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), HTLV-1-associated uveitis, Sjögren’s syndrome,
arthropathy, myopathy, and alveolitis; (2) a neoplasm, i.e., adult
T-cell leukemia/lymphoma (ATLL); and (3) other infectious
complications such as scabies, strongyloidiasis, and tuberculosis.
Despite the frequency of the infection and the severity of the
associated diseases, HTLV-1 remains a neglected health problem
and many questions remain unsolved.
As most of the people infected with HTLV-1 remain
asymptomatic, carrying the virus cannot be the only cause of
HTLV-1-associated diseases. Some studies have linked specific
virus strains with an increased risk of HAM/TSP and ATLL
(Furukawa et al., 2000). Nevertheless, it is unlikely that virus
genotype plays a major role in the pathogenesis because HTLV-
1 is a genetically stable virus with little sequence variation and
because there are reports of individuals with the same virus strain
but with very different clinical outcomes (Daenke et al., 1990; Van
Dooren et al., 2004). On the other hand, there is strong evidence
that the proviral load, i.e., the proportion of peripheral blood
mononuclear cells that carry the HTLV-1 provirus, is associated
with the presence of complications (Nagai et al., 1998). This
proviral load depends on the strength of an individual’s cytotoxic
T-lymphocyte response to HTLV-1, which is associated with the
genetically determined human leucocyte antigen (HLA) class 1
types. Associations have indeed been found between specificHLA
types and the proviral load (e.g., HLA-A∗02), HAM/TSP (e.g.,
HLA-DRB1∗0101), and ATLL (e.g., HLA-A∗26) (Jeffery et al.,
1999; Sonoda et al., 2011; Assone et al., 2016). These associations,
however, could not be replicated across populations (Talledo
et al., 2010). Other human genes that could play a role in the
pathogenesis include those of nuclear factor kappa B and natural-
killer group 2 member D (Talledo et al., 2012). In addition
to viral and human genetic factors, there is evidence that the
route of HTLV-1 transmission and the duration of exposure
may influence the outcome of HTLV-1 infection (Murphy et al.,
1989; Maloney et al., 1998). Finally, environmental factors and
exposure to co-infections could also play a role (Leon-S and
Zaninovic, 1995; Plumelle et al., 1997; LaGrenade et al., 1998).
However, in spite of the advances in the understanding of the
pathogenesis of HAM/TSP and ATLL, it is still unclear why some
individuals develop complications while others do not.
HTLV-1 can be transmitted via contaminated blood products,
organ transplantation, sexual intercourse, and from mother
to child mainly through breastfeeding. The latter two routes
of transmission explain the clustering of HTLV-1 infection
in families. Whether familial clustering of HTLV-1-associated
diseases can be explained by familial transmission only or
whether there are additional factors involved remains a matter
of debate. ATLL and HAM/TSP were originally described as
sporadic entities. However, soon after the initial characterization
of these diseases, reports of families in which several members
had ATLL or HAM/TSP started to appear. One possibility is
that HTLV-1-associated diseases are distributed randomly in the
population of HTLV-1 carriers and that in a few families, more
than one case of disease occurs due to chance. However, it is
also possible that members of the same family share viral, genetic
or environmental factors that increase the risk of associated
diseases. Family aggregation studies have proven to be a useful
component of the research into diseases such as multiple sclerosis
(Gourraud et al., 2011), autoimmune diseases (Cárdenas-Roldán
et al., 2013), and cancer (Kicin´ski et al., 2011; Wan et al.,
2015). Evidence from such studies can give new insights in
disease mechanisms and improve the quality of diagnosis and
counseling.
To explore what is known about family aggregation of HTLV-
1-associated diseases, we undertook a systematic review. We
aimed at answering if, where and when family aggregation of
different HTLV-1-associated diseases had been reported, which
relatives were affected and which hypotheses had been proposed
to explain the family aggregation.
METHODS
To obtain published information about family aggregation of
HTLV-1-associated diseases, we searched MEDLINE (through
PubMed), abstract books of HTLV conferences and reference lists
of selected papers. To retrieve the abstracts, we hand-searched the
abstract books of eleven conferences onHTLV and related viruses
organized between 1994 and 2015.
The PubMed search was done in January 2015 and combined
three types of search terms: terms indicating (1) HTLV-1
infection, (2) HTLV-1-associated diseases, and (3) family studies.
The detailed search strategy is given as Supplementary Material.
The search was not restricted by publication date, language, or
study design.
Family aggregation of HTLV-1-associated diseases was defined
as the occurrence of an HTLV-1-associated disease in more
than one member of a family. We used an extensive definition
of a family, including in-laws as well as blood relatives. For
the literature search, the following conditions were considered
to be HTLV-1-associated diseases: HAM/TSP, ATLL, HTLV-1-
associated uveitis, and infective dermatitis.
Two reviewers (CA and KV) independently screened all titles
and abstracts of the records retrieved through the PubMed
search. One reviewer (CA) then read the full text of the
preselected records. Doubts and discrepancies in the selection
of records were solved through the discussion among two
reviewers (CA and KV). All records that mentioned HTLV-
1-associated diseases in more than one member of the same
family were included. When the same families were identified
in more than one record, we selected the record that contained
more information and excluded the other. When both records
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contained the same amount of information, we selected the
earliest report.
Data were extracted using a pre-designed form. The
following information was extracted from the selected
records: study design, year, country, number of families,
number of relatives affected by HTLV-1-associated diseases,
relationship between affected relatives, and hypotheses
proposed to explain family aggregation of HTLV-1-associated
diseases.
For the analysis, we first assessed the characteristics of the
selected records, including study design. Next, we combined
all those studies that gave detailed information about concrete
families in which more than one person had an HTLV-1-
associated disease. We presented this information as the number
of families with particular diseases, particular family relationships
or both. Finally, for those studies that were designed to describe
or explain family aggregation, we summarized the results of the
individual records.
From planning to reporting this review, the recommendations
of the PRISMA statement (Preferred Reporting Items for
Systematic Reviews andMeta-Analysis; Liberati et al., 2009) were
taken into account. However, not all PRISMA items could be
followed because they are about intervention studies, which are
not the focus of the present review. We did not formally assess
the risk of bias but instead, described the study design for all the
included records. No protocol was registered for this review and
a meta-analysis was not done.
RESULTS
Study Selection
The MEDLINE search retrieved 1112 records (Figure 1).
Reviewing the reference lists of the selected articles yielded five
additional records and reviewing 2614 abstracts from HTLV
conferences yielded 21 additional records. After removal of
duplicate publications, 1116 records passed on to the screening
FIGURE 1 | Flow diagram summarizing systematic search and study selection.
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phase. After examination of titles and abstracts, 956 records were
excluded because of the following reasons: (1) not about HTLV-
1; (2) not focusing on HTLV-1-associated diseases; and (3) not
reporting information in families. For the remaining 160 records,
we assessed the eligibility of the full-text articles and excluded
an additional 86 records based on the same criteria. Figure 1
illustrates the selection process. We finally selected 74 records (61
peer-reviewed articles and 13 abstracts from HTLV conferences)
for further analysis.
Study Characteristics
Between 1982 and 2015, 74 studies reported family aggregation
of HTLV-1-associated diseases. Thirteen of them were designed
to identify or explain family aggregation, including 10 cross-
sectional studies (Kondo et al., 1985; Matsuo et al., 1989;
Kayembe et al., 1990; Tajima, 1990; Bhigjee et al., 1995; Iwanaga
et al., 1995; Pombo-de-Oliveira et al., 2001; Cabada et al., 2007;
Alvarez et al., 2014; Nozuma et al., 2014), two reviews (Manns
and Qasba, 1999; Shoeibi et al., 2013), and one cohort study
(Iwanaga et al., 2010). The remaining 61 records were either case
reports or reports of family clusters that were identified within
other epidemiological studies. The study design of the records
included in this review is summarized in Table 1.
More than half of the reports came from HTLV-1-endemic
countries, mainly Japan (n = 30) and Brazil (n = 10). Reports
from non-endemic countries (n = 17) described HTLV-1-
associated diseases in migrants from endemic regions or in
specific ethnic groups (Denic et al., 1988, 1990; Ratner and Poiesz,
1988; Mowbray et al., 1989; Dixon et al., 1990; Nightingale and
Desselberger, 1990; Nomura et al., 1990; Ratner et al., 1990;
Salazar-Grueso et al., 1990; Major et al., 1993; Matutes et al., 1995;
Hu et al., 1998; Prates et al., 2000; Biglione et al., 2003; Mahé
et al., 2004; Dosik and Wilson, 2009; Díaz Torres et al., 2010).
Table 2 summarizes the countries where family aggregation of
HTLV-1-associated diseases has been reported.
Overview of Families
Overall, there were 270 families in which more than one family
member had an HTLV-1-associated disease (Table 3). In 223 of
these families (83%), several family members suffered from the
same disease, i.e., ATLL (115 families), HAM/TSP (102 families),
or another disease (6 families). In 47 families (17%), different
family members suffered from different diseases. Some of the
included records also described the coexistence of more than one
HTLV-1-associated disease in the same person (Supplementary
Table).
The number of affected individuals per family ranged from
two to seven. Most of the family clusters (n = 144) contained
two to four affected individuals. However, we also found reports
of more complex families in which there were three or more
different associated diseases (5 families), five or more affected
individuals (6 families), and/or affected individuals in three or
more generations (3 families).
Family aggregation has been reported in blood relatives and
in in-laws. The type of family relationship between the cases was
given for 121 out of the 270 families included in this review
(45%). In 110 families, the diseases affected only blood relatives,
TABLE 1 | Design of the included studies.
Study
design
Number
of records
References
Case
report
56
Of one
family
46 Imamura et al., 1982; Miyoshi et al., 1982; Kikuchi
et al., 1983; Sarin et al., 1983; Kawano et al.,
1984; Miyamoto et al., 1985; Taguchi et al., 1985;
Yamaguchi et al., 1985; Maekawa et al., 1986;
Denic et al., 1988; Ratner and Poiesz, 1988;
Sakuma et al., 1988; McKhann et al., 1989;
Sanada et al., 1989; Shoji et al., 1989; Denic et al.,
1990; Dixon et al., 1990; Nightingale and
Desselberger, 1990; Nomura et al., 1990; Ratner
et al., 1990; Salazar-Grueso et al., 1990; Uozumi
et al., 1991; Cavalcanti et al., 1993; Major et al.,
1993; Wilks et al., 1993; Hokezu et al., 1994;
Matutes et al., 1995; LaGrenade et al., 1996;
Cordoliani et al., 1998; Hu et al., 1998; Gonçalves
et al., 1999; Shimizu, 1999; Nakane et al., 2000;
Prates et al., 2000; Wilks et al., 2001; Araújo et al.,
2002; Biglione et al., 2003; Ribas et al., 2003;
Sawa et al., 2005; Nobre et al., 2006; Nomura
et al., 2006; Cloves et al., 2009; Daisley and
Charles, 2009; Dosik and Wilson, 2009; Suite
et al., 2009; Alvarez et al., 2011
Of more
than one
family
10 Ichimaru et al., 1986; Miyai et al., 1987; Mori et al.,
1988; Matsuo et al., 1989; Araki et al., 1993; Blank
et al., 1993; Plumelle et al., 1993; Cartier et al.,
1998; Nagashima et al., 2001; da Silva et al., 2013
Cross-
sectional
study
15 Kondo et al., 1985; Mowbray et al., 1989;
Kayembe et al., 1990; Tajima, 1990; Bhigjee et al.,
1995; Carvalho et al., 1995; Iwanaga et al., 1995;
Pombo-de-Oliveira et al., 2001; Furukawa et al.,
2003; Mahé et al., 2004; Primo et al., 2005;
Cabada et al., 2007; Díaz Torres et al., 2010;
Alvarez et al., 2014; Nozuma et al., 2014
Cohort
study
1 Iwanaga et al., 2010
Review 2 Manns and Qasba, 1999; Shoeibi et al., 2013
in six families only in-laws, and in five families, the diseases
affected both blood relatives and in-laws. In the 110 families
in which only blood relatives were affected, the diseases that
clustered most frequently were ATLL (44 families), HAM/TSP
(27 families), HAM/TSP+ infective dermatitis (17 families), and
HAM/TSP + ATLL (13 families). The six families in which only
in-laws developed diseases comprised three pairs of spouses with
ATLL and three pairs of spouses in which the husband had ATLL
and the wife had HAM/TSP (Table 3).
Detailed relationships between the cases were given in 51
family clusters of ATLL, 47 clusters of HAM/TSP, and 17 of ATLL
+HAM/TSP (Table 4). For ATLL, the most frequent pattern was
a cluster of two or more affected siblings (26 out of 51 clusters,
51%). Parent-child pairs with ATLL were also relatively common
(11 of 51 clusters, 22%). For HAM/TSP, the predominant cluster
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type was that of one affected parent with one or more affected
children (29 of 47 clusters, 62%). In families with ATLL +
HAM/TSP, most of the cases corresponded to parent-child pairs
(6 of 17 clusters, 35%) or sibling pairs (5 of 17 clusters, 29%).
Family Aggregation of HTLV-1-Associated
Diseases
Thirteen studies contained elements in their design that allowed
to describe the family aggregation of HTLV-1-associated diseases
in a systematic way. Nine of these studies reported which
proportion of patients with ATLL or HAM/TSP had at least one
relative with the same disease (Table 5). The proportion of ATLL
patients with a family history of ATLL ranged from 2 to 26%.
The proportion of HAM/TSP patients with a family history of
HAM/TSP ranged from 1 to 48% (Table 5).
The remaining four aggregation studies used different
approaches. Iwanaga et al. conducted a large cohort study in
Japan. They analyzed the information of 1218 HTLV-1-infected
subjects who did not have HAM/TSP or ATLL at the beginning
of the study. The majority of the study participants (65%) were
women; 55% were born in Southern Japan and the median
age at enrollment was 60 years for women and 58 years for
men. During follow up, 14 study participants developed ATLL.
The incidence of ATLL in this cohort was 7 per 1000 person-
years. Onmultivariable Cox regression analysis, four factors were
significantly associated with an increased hazard of developing
ATLL: high baseline proviral load, advanced age, first diagnosis
of HTLV-1 infection during treatment for other diseases, and
family history of ATLL. After adjustment for other associated
factors, the hazard of developing ATLL was 12 times higher
in those HTLV-1 carriers who had a family history of ATLL
compared to those who did not have such a family history (hazard
ratio 12.1; 95% confidence interval 2.3–64.7) (Iwanaga et al.,
2010).
Alvarez et al. set out to evaluate if having a relative
with HAM/TSP increases the risk of having HAM/TSP. They
expected that the frequency of HAM/TSP among relatives of
HAM/TSP patients would be higher than that among relatives
of asymptomatic HTLV-1 carriers. In a study in Peru, they found
30 HAM/TSP cases (9%) among 318 HTLV-1-positive relatives
of 334 HAM/TSP patients compared to 15 HAM/TSP cases
(7%) among 204 HTLV-1-positive relatives of 230 asymptomatic
HTLV-1 carriers. This difference was not statistically significant.
The authors concluded that HAM/TSP is usually sporadic but
that in some particular families there are HAM/TSP clusters
(Alvarez et al., 2014).
Manns et al. started from the hypothesis that human genetic
characteristics are a causal factor for HTLV-1-associated diseases.
They reviewed the literature to check if the patterns of disease
aggregation in families supported this hypothesis. They identified
19 families with multiple cases of ATLL and 16 families with
multiple cases of HAM/TSP. The authors concluded that the
patterns of disease aggregation differed between ATLL and
HAM/TSP families, but they did not find strong arguments in
favor of a genetic basis for the aggregation (Manns and Qasba,
1999).
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TABLE 5 | Proportion of patients with HTLV-1-associated diseases who have a relative with the same disease.
Disease Country Number of cases Number (proportion) of cases who have at
least one relative with the same disease
References
ATLL Japan 657 14 (2%) Tajima, 1990
ATLL Japan 23 2 (9%) Iwanaga et al., 1995
ATLL Japan 38 9 (24%) Kondo et al., 1985
ATLL Brazil 82 3 (4%) Pombo-de-Oliveira et al., 2001
ATLL Peru 42 11 (26%) Cabada et al., 2007
HAM/TSP Japan 21 6 (29%) Matsuo et al., 1989
HAM/TSP South Africa 124 1 (1%) Bhigjee et al., 1995
HAM/TSP DRC 21 10 (48%) Kayembe et al., 1990
HAM/TSP Iran NA NA (9–25%) Shoeibi et al., 2013
ATLL, adult T-cell leukemia/lymphoma; HAM/TSP, HTLV-1-associated myelopathy/tropical spastic paraparesis; NA: not available.
Nozuma et al. conducted a study in Japan in which they
compared clinical and laboratory characteristics of 124 sporadic
HAM/TSP cases with those of 40 HAM/TSP patients with a
family history of HAM/TSP. The HAM/TSP cases with a family
history of HAM/TSP had a slower rate of HAM/TSP progression
and an earlier age of onset (mean 41.3 years) than sporadic cases
(mean 51.6 years). There was no difference in HTLV-1 proviral
load between the two groups (Nozuma et al., 2014). Four other
records mention an early age of onset of HAM/TSP in some
relatives of HAM/TSP patients (Miyai et al., 1987; McKhann
et al., 1989; Kayembe et al., 1990; Cartier et al., 1998), but only
Nozuma et al. evaluated this in a systematic way (Nozuma et al.,
2014).
Hypotheses to Explain Family Aggregation
Diverse hypotheses were proposed in the included papers
to explain family aggregation of HTLV-1-associated diseases.
Clustering of cases in families was attributed to viral genetic
factors, host genetic and immune factors, transmission routes,
environmental factors or a combination of these (Table 6).
With regard to the virus, some authors thought of specific
strains causing either ATLL or HAM/TSP. Mahé et al. suggested
that there were specific point mutations or “familial signatures”
in family clusters of infective dermatitis (Mahé et al., 2004).
Along the same line, Renjifo et al. suggested specific rex and
env mutations in a cluster of three HAM/TSP patients (two
parents and their child; Renjifo et al., 1995). On the other
hand, there was also a report of a family with different clinical
outcomes (father with ATLL, mother with HAM/TSP, and three
asymptomatic HTLV-1-infected children) that could not be
explained by different viral strains. In this family, Major et al.
found a complete sequence conservation of the tax gene (Major
et al., 1993).
At the level of the human host, many authors mentioned the
possible causal role of genetic, and immunological factors. In 14
records, it was specified what these factors could be, e.g., specific
HLA alleles, or an exacerbated humoral response. One study
checked HLA haplotypes in a family with infective dermatitis and
HAM/TSP (LaGrenade et al., 1996). They found that a mother
with infective dermatitis+HAM/TSP and her two children, a son
with infective dermatitis + pyramidal tract involvement and an
asymptomatic son, shared the same HLA alleles while their other
asymptomatic HTLV-1-infected relatives presented other HLAs.
Furthermore, the HLAs shared by the mother and her children
had been linked to HAM/TSP in Japanese patients (Usuku et al.,
1988). Similarly, Nomura et al. found that two siblings coming
from a family in which six siblings presented ATLL shared the
same HLA alleles, which had been proposed to predispose to
ATLL (Yashiki et al., 2001; Nomura et al., 2006).
Nakane et al. explored both the HTLV-1 sequences and the
HLA genotypes and their role in the clinical outcome of HTLV-1.
In a family of four HTLV-1 carriers (an asymptomatic mother,
two brothers with HAM/TSP—one of them a twin—and an
asymptomatic twin), they found that the monozygotic twins with
different clinical outcomes carried different viral strains. They
also found that different HLA molecules were expressed in the
mother and her children (Nakane et al., 2000).
Information about the proviral load was given in four records,
but different methods (based on tax gene, pX gene, or whole
genome) were used to measure this (Wilks et al., 2001; Furukawa
et al., 2003; Iwanaga et al., 2010; Nozuma et al., 2014). In two
studies, asymptomatic HTLV-1-carriers with a family history of
ATLL or HAM/TSP were found to have a higher proviral load
than those without such a family history (Furukawa et al., 2003;
Iwanaga et al., 2010).
The route of HTLV-1 transmission was also put forward as
a factor that could influence the outcome of infection, through
the infective dose (provirus load in breastmilk) or the timing
of HTLV-1 infection (during childhood vs. during adulthood;
Ichimaru et al., 1986; Mori et al., 1988; Matsuo et al., 1989;
Salazar-Grueso et al., 1990;Wilks et al., 1993; da Silva et al., 2013).
None of the included studies explored this further. Finally, five
records mentioned that environmental factors could play a role
but this was not further specified or studied (Table 6).
DISCUSSION
The occurrence of several family members affected by HTLV-1-
associated diseases has been reported ever since the discovery
of HTLV-1 in the early 1980s (Imamura et al., 1982; Miyoshi
Frontiers in Microbiology | www.frontiersin.org 9 October 2016 | Volume 7 | Article 1674
Alvarez et al. Family Aggregation of HTLV-1-Associated Diseases
TABLE 6 | Hypotheses proposed to explain family aggregation of HTLV-1-associated diseases.
Factor Hypothesis References*
Virus genetics Particular retroviral strains,
specific virus
subgroups/mutations/deletions
Ichimaru et al., 1986; Cavalcanti et al., 1993; Major et al., 1993; Nakane et al., 2000; Mahé et al.,
2004; Nomura et al., 2006
Viral strains specific for ATLL Maekawa et al., 1986; Nomura et al., 1990; Ratner et al., 1990
Neurotropic viral strains Miyai et al., 1987; Kayembe et al., 1990; Salazar-Grueso et al., 1990
Host Genetic and/or
Immune
factors
Specific HLA alleles Shoji et al., 1989; Uozumi et al., 1991; Blank et al., 1993; LaGrenade et al., 1996; Nakane et al.,
2000; Pombo-de-Oliveira et al., 2001; Primo et al., 2005; Sawa et al., 2005; Nomura et al., 2006
Genetic susceptibility for
disease (not specified)
Imamura et al., 1982; Miyai et al., 1987; Kayembe et al., 1990; Salazar-Grueso et al., 1990; Araki
et al., 1993; Cavalcanti et al., 1993; Wilks et al., 1993; Cartier et al., 1998; Cordoliani et al.,
1998; Wilks et al., 2001; Mahé et al., 2004; Dosik and Wilson, 2009; Alvarez et al., 2011
Different immunogenetic
backgrounds leading to
different disease outcomes
Shoji et al., 1989
Specific immune
characteristics in patients
Wilks et al., 1993; Hokezu et al., 1994; Díaz Torres et al., 2010
Exacerbated humoral
response
Sarin et al., 1983; Ratner and Poiesz, 1988; Cartier et al., 1998; Pombo-de-Oliveira et al., 2001;
Wilks et al., 2001; Primo et al., 2005; Cloves et al., 2009; Nozuma et al., 2014
Particular integration sites Salazar-Grueso et al., 1990
Transmission
routes
Vertical (milk-borne)
transmission
Mori et al., 1988; Matsuo et al., 1989
High provirus load in
breastmilk, fluctuating
viremia in mother
Salazar-Grueso et al., 1990; da Silva et al., 2013
Infection in childhood, long
incubation period
Ichimaru et al., 1986; Maekawa et al., 1986; Wilks et al., 1993
Not specified Manns and Qasba, 1999
Environment Not specified Kayembe et al., 1990; Cavalcanti et al., 1993; Mahé et al., 2004; Dosik and Wilson, 2009;
Alvarez et al., 2011
ATLL, adult T-cell leukemia/lymphoma; HLA, human leukocyte antigen.
*Some studies propose more than one hypothesis.
et al., 1982). Descriptions of family clusters come from all
continents. Known HTLV-1-endemic regions such as Japan and
Brazil and places with many immigrants from HTLV-1-endemic
regions such as the United Kingdom are particularly well-
represented among the reports. However, there are also other
HTLV-1-endemic regions such as Romania for which we did
not find any reports of family aggregation (Laperche et al.,
2009; European Centre for Disease Prevention Control, 2015).
Although our search retrievedmany records (n= 74), few studies
were specifically designed to investigate family aggregation.
Nonetheless, we found descriptions of 270 concrete families
in which more than one person had an HTLV-1-associated
disease. The specific diseases and the relationships within the
affected families varied, but the predominant situation was that
several blood relatives suffered from the sameHTLV-1-associated
disease. The majority of the reports were about ATLL, HAM/TSP,
or both.
An important limitation of this review is that the majority
of the included studies are case reports describing one or
several families. In addition, some of the included information
came from conference abstracts. We decided not to exclude
studies based on study design or risk of bias in order to
give a broad overview of all the available information. As a
consequence, the findings have to be interpreted with caution.
A second limitation is that the extent to which the families
were studied and the quality of the diagnosis of HTLV-1-
associated diseases varied across the included reports. For
example, some authors only described cases with a diagnosis
based on clear clinical and laboratory arguments whereas
others also included cases based on an interview about their
relatives. In addition, many authors did not report how they
had diagnosed the HTLV-1-associated diseases. As a rule, we
accepted the diagnoses as they were described in the included
papers, but sometimes it was difficult to decide what to do with
diagnoses such as “pre-ATLL” or “non-HAM/TSP neurological
disorders.” Furthermore, several asymptomatic HTLV-1-positive
individuals could develop HTLV-1-associated diseases later on.
Third, there is the issue of publication bias, which may work
in two directions. Under-reporting is likely because HTLV-1
infection is a neglected topic which is frequent in some areas
without a strong publication record. Many cases of HTLV-1-
associated diseases might never be diagnosed, and outside Japan,
there are no systematic registries of HTLV-1-associated diseases.
On the other hand, over-reporting is also possible because the
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most extreme or unusual family clusters may have a higher
chance of being published. Finally, it is possible that relatives of
people with HTLV-1-associated diseases get screened for HTLV-1
more frequently than relatives of asymptomatic HTLV-1 carriers
and that, consequently, they get better access to medical care
and diagnosis of HTLV-1-associated diseases. If true, this may
increase the chance of finding family clusters.
The design and execution of studies on family aggregation
of HTLV-1-associated diseases are challenging for many reasons.
Such studies require serological and clinical evaluations of many
family members, some of whom may not be available or not
willing to participate. In addition, in most families, only some
individuals are HTLV-1 infected and only those who are infected
are at risk of developing complications. The fact that the
patterns of infection differ across families adds an extra layer
of complexity to the study of family aggregation of HTLV-1-
associated diseases, as aggregation has to be investigated on top
of the probability to be infected within a family. Finally, as the
incubation time of HTLV-1-associated diseases can be very long
and there are no markers that predict disease occurrence, robust
studies will require large sample sizes, long follow-up periods or
both. Such large population-based family studies have been done
for other diseases such as multiple sclerosis in Sweden, systemic
lupus erythematosus in Taiwan and liver cancer in China, but not
yet for HTLV-1 (Hemminki et al., 2009; Kuo et al., 2015; Wan
et al., 2015).
The central question of this review was: do HTLV-1-associated
diseases run in families? Or phrased differently: does having a
relative with an HTLV-1-associated disease increase an HTLV-
1 carrier’s risk to develop an associated disease as well? The
mere number of records about the topic (n = 74) as well as
the number of reported family clusters (n = 270) suggest that
HTLV-1-associated diseases do occur in families more frequently
than would be expected by chance. Moreover, one cohort study
showed that having a family history of ATLL increases the risk
of developing ATLL (Iwanaga et al., 2010). This cohort study
was comprehensive and well-designed to answer the question
of family aggregation and contributes the strongest evidence
(Iwanaga et al., 2010). The majority of the other studies that we
retrieved were case reports or case series in which the risk of bias
is known to be high. Therefore, we considered that the overall
strength of the evidence was weak.
Familial predisposition for a disease is sometimes used as
a surrogate measure for the interaction between genetic and
environmental factors (Nielsen et al., 2015), and in this case
also viral factors. The fact that there were many clusters of
blood relatives with ATLL or HAM/TSP supports the human
genetic component in the causal model of HTLV-1-associated
diseases. On the other hand, this human genetic component is
clearly not sufficient to explain the development of these diseases,
because (1) there are also clusters of in-laws, (2) there are families
in which different relatives have different diseases, and (3) the
concordance rate of monozygotic twins is <100% (Nakane et al.,
2000; Alvarez et al., 2011). Furthermore, the genetic factors that
have been identified so far in association with ATLL orHAM/TSP
do not have a very strong effect on disease risk or do not have
the same effect in all populations (Vine et al., 2002; Talledo
et al., 2010).Therefore, ATLL and HAM/TSP seem to be complex
diseases just like among others diabetes, obesity, asthma, multiple
sclerosis, and other autoimmune disorders, which depend on
the effects of multiple genes in combination with lifestyle and
environmental factors. Such complex diseases typically cluster in
families, but without a simple pattern of inheritance.
Vertical transmission has been linked to the development
of ATLL (Murphy et al., 1989) and horizontal transmission to
HAM/TSP (Maloney et al., 1998). Similarly, transmission routes
have been proposed to play a role in the family aggregation of
HTLV-1-associated diseases. In the case of ATLL, our findings
are in line with this hypothesis, as most of the ATLL clusters
consisted of siblings who most likely acquired the infection
vertically. In the case of HAM/TSP, we had expected to find
more clusters of in-laws; instead, the majority of the HAM/TSP
clusters were parent-child or sibling pairs. It is important to note
in this context that there may be differences between familial
and sporadic HAM/TSP: familial HAM/TSP has been reported
to start at an earlier age and to be less severe than sporadic
HAM/TSP (Nozuma et al., 2014). One way of bringing several
causal components together would be to think of HAM/TSP as a
disease that occurs in people (1) with a genetic tendency (based
onHLA among other genes) to develop inflammatory conditions,
(2) carrying anHTLV-1 strain with strong expression of antigenic
Tax protein, and (3) infected with HTLV-1 via sexual intercourse
(sporadic, late onset HAM/TSP) or via breastfeeding (familial,
early onset HAM/TSP). ATLL could then be seen as a disease that
occurs in people (1) with genetic susceptibility (based on HLA
among other genes) to infections, (2) carrying an HTLV-1 strain
with dominant HTLV-1 bZIP factor and weak Tax expression,
and (3) infected with HTLV-1 mainly via breastfeeding.
Environmental factors were mentioned several times as a
possible and partial explanation of family aggregation of HTLV-
1-associated diseases. However, none of the included records
explored this further. It is noticeable that co-infections were
not mentioned in this context, because co-infections may
also run in families and because specific co-infections have
been linked to HTLV-1-associated diseases before, particularly
infective dermatitis with HAM/TSP (Bittencourt and de Oliveira,
2010), and strongyloidiasis with ATLL (Plumelle et al., 1997).
Furthermore, there is evidence that HTLV-1 can influence the
outcome and severity of other infections such as tuberculosis
(Verdonck et al., 2007a), HIV (Brites et al., 2001; Silva et al.,
2009), and hepatitis C (Castro and Roger, 2016). Although
none of the records suggested the role of co-infections in
explaining family aggregation, they did report families in which
co-infections (i.e., strongyloidiasis and infective dermatitis) were
present (Blank et al., 1993; Wilks et al., 1993; LaGrenade et al.,
1996; Gonçalves et al., 1999; Araújo et al., 2002; Mahé et al., 2004;
Primo et al., 2005; Nobre et al., 2006; Suite et al., 2009; Alvarez
et al., 2011; da Silva et al., 2013).
The implications of this review for clinical practice relate
mainly to counseling. When a person is diagnosed with an
HTLV-1-associated disease, a family study is usually done.
Frequently asked questions during counseling include: “Will I
or my relatives develop the same disease?” and “What can we
do to prevent HTLV-1-associated diseases?” Given the limited
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knowledge of the factors implicated in the development of HTLV-
1-associated diseases and, in consequence, the lack of measures
to prevent them, it remains difficult to answer such questions.
However, we think that based on this review, the possibility of a
familial predisposition to HTLV-1-associated diseases should be
mentioned during counseling. In addition, close clinical follow
up of the HTLV-1-infected relatives of patients with ATLL or
HAM/TSP appears to be indicated. Potential biomarkers such
as the proviral load (Nagai et al., 1998) and cytokine profiles
(Starling et al., 2013) deserve further study as they could make
counseling more meaningful.
This review also has implications for research. ATLL
and HAM/TSP seem to be complex diseases, which are
notably difficult to study. Further research on ATLL and
HAM/TSP in families should benefit from important advances
in research about other complex diseases in which specific gene-
environment interactions are being investigated and for which
new methods are being developed (Esposito et al., 2015; Park
and Kim, 2015). Family studies could contribute to the research
about the causes of HTLV-1-associated diseases, but it is clear that
in order to be really useful, future studies will have to be large,
well-designed, and hypothesis driven.
In conclusion, families with several cases of HTLV-1-
associated diseases have caught the attention of clinicians and
researchers in different times and different continents. Although
the evidence is weak, it does suggest that HTLV-1-associated
diseases sometimes cluster in families.
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